Navigation path

Pharmaceuticals - Union Register

  

Register of orphan medicinal products


GRANTED  

Product information

Autologous CD4+ and CD8+ T cells expressing a CD19-specific chimeric antigen receptor

EU orphan designation number: EU/3/17/1890   
Active ingredient: Autologous CD4+ and CD8+ T cells expressing a CD19-specific chimeric antigen receptor
Indication: Treatment of diffuse large B-cell lymphoma
Sponsor: Celgene Europe B.V.
Winthontlaan 6 N, 3526 KV Utrecht, Nederland

   Public summary of scientific opinion    

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
19/07/2017 Orphan designation EMA/OD/045/17 (2017)5154 of 17/07/2017
14/02/2019 Transfer of orphan designation EMA/OD/0000003329 (2019)1349 of 12/02/2019